863671-49-2

Upstream product

• 863671-47-0 tert-butyl (2S)-2-({5-[(4-methylphenyl)sulfonyl]-1H-tetrazol-1-yl}methyl)pyrrolidine-1-carboxylate 
• 168049-26-1 tert-butyl (2S)-2-(azidomethyl)-1-pyrrolidinecarboxylate 
• 863671-48-1 (S)-Boc-2-(5-phenylsulfanyltetrazol-1′-ylmethyl)pyrrolidine 

Downstream Products

• 863671-50-5 {1-[2-(5-phenylsulfanyl-tetrazol-1-ylmethyl)-pyrrolidine-carbonyl]-2-ynyloxy-propyl}-carbamic acid allyl ester 

Relevant academic research and scientific papers

MITOCHONDRIAL TARGETED STIMULATORS OF APOPTOSIS

Pro-apoptotic compounds having a tripartite structure: [in-line-formulae]A-L-B[/in-line-formulae] are disclosed. In these compounds A is an IBM mimetic moiety; L is a linker and B is a moiety that binds to a protein on the outer mitochondrial membrane. The compounds are useful for inducing cell apoptosis and therefore treating cancer. An example of such a compound is

Dimeric small molecule potentiators of apoptosis

Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of the dimeric mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.